About Genolux
Founded in Baltimore in 2024 by computational biologists who believed protein-protein interaction surfaces deserved purpose-built modeling tools.
The Problem We Set Out to Solve
Dr. Elena Voss and her co-founders spent years running PPI drug discovery programs using tools designed for enzyme inhibitors. The frustration was consistent: general-purpose docking scores correlated poorly with PPI disruption data.
They built Genolux to address this specifically — not a general computational platform, but a focused PPI surface modeling engine for oncology. The founding premise: the scoring function problem in PPI drug discovery is solvable, but only if you build for interfaces, not adapt tools designed for pockets.
How We Work
Scientific Honesty
We publish benchmarks including failure modes. A score is only useful if you know when it's wrong. Internal validation results are clearly labeled as internal — not independent replication.
Computational Rigour
Methodology derived from peer-reviewed structure bioinformatics — no black-box models without interpretable output. Every disruption score has a structural rationale attached.
Focused Scope
We do one thing: PPI surface modeling for oncology. No feature sprawl. No enterprise pivot. Focus is the only way to do this problem well at angel stage.
Baltimore, Maryland
Located in downtown Baltimore, Genolux operates close to the Johns Hopkins and University of Maryland School of Medicine academic medical centers — proximity to translational oncology research that directly informs our target selection and validation partnerships.
Meet the Team
Computational biologists, medicinal chemists, and oncology biologists building the tools PPI drug discovery needs.
Meet the Team